MA35859B1 - Formulation de poudre sèche comportant un corticostéroïde et un bêta-adrénergique pour administration par inhalation - Google Patents

Formulation de poudre sèche comportant un corticostéroïde et un bêta-adrénergique pour administration par inhalation

Info

Publication number
MA35859B1
MA35859B1 MA37200A MA37200A MA35859B1 MA 35859 B1 MA35859 B1 MA 35859B1 MA 37200 A MA37200 A MA 37200A MA 37200 A MA37200 A MA 37200A MA 35859 B1 MA35859 B1 MA 35859B1
Authority
MA
Morocco
Prior art keywords
corticosteroid
dry powder
adrenergic
inhalation
beta
Prior art date
Application number
MA37200A
Other languages
English (en)
Inventor
Elisa Monari
Anna Maria Cantarelli
Daniela Cocconi
Irene Pasquali
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35859(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA35859B1 publication Critical patent/MA35859B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une formulation de poudre sèche qui comporte un corticostéroïde et un médicament bêta2-adrénergique en combinaison, son processus de préparation et ses utilisations thérapeutiques.
MA37200A 2012-01-25 2014-07-11 Formulation de poudre sèche comportant un corticostéroïde et un bêta-adrénergique pour administration par inhalation MA35859B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152392 2012-01-25
PCT/EP2013/051187 WO2013110632A1 (fr) 2012-01-25 2013-01-23 Formulation de poudre sèche comportant un corticostéroïde et un bêta-adrénergique pour administration par inhalation

Publications (1)

Publication Number Publication Date
MA35859B1 true MA35859B1 (fr) 2014-12-01

Family

ID=47715987

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37200A MA35859B1 (fr) 2012-01-25 2014-07-11 Formulation de poudre sèche comportant un corticostéroïde et un bêta-adrénergique pour administration par inhalation

Country Status (37)

Country Link
US (3) US10028964B2 (fr)
EP (7) EP3527198B1 (fr)
JP (1) JP6104282B2 (fr)
KR (3) KR101560288B1 (fr)
CN (2) CN105726548B (fr)
AR (1) AR089805A1 (fr)
AU (1) AU2013211656B2 (fr)
BR (1) BR112014017481A8 (fr)
CA (1) CA2862548C (fr)
CL (1) CL2014001966A1 (fr)
CO (1) CO7010836A2 (fr)
CY (3) CY1120684T1 (fr)
DK (6) DK3527197T3 (fr)
EA (2) EA026267B1 (fr)
ES (6) ES2996893T3 (fr)
FI (2) FI3412277T3 (fr)
GE (1) GEP201706767B (fr)
HR (6) HRP20221432T1 (fr)
HU (6) HUE069624T2 (fr)
IL (1) IL233784A0 (fr)
LT (5) LT3527197T (fr)
MA (1) MA35859B1 (fr)
MX (2) MX355729B (fr)
MY (1) MY165888A (fr)
NZ (1) NZ627837A (fr)
PE (1) PE20141703A1 (fr)
PH (1) PH12014501565B1 (fr)
PL (6) PL3527198T3 (fr)
PT (6) PT3527196T (fr)
RS (5) RS63952B1 (fr)
SG (1) SG11201404350PA (fr)
SI (3) SI2806855T1 (fr)
TN (1) TN2014000322A1 (fr)
TW (1) TWI559940B (fr)
UA (1) UA115543C2 (fr)
WO (1) WO2013110632A1 (fr)
ZA (1) ZA201405464B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE069624T2 (hu) * 2012-01-25 2025-03-28 Chiesi Farm Spa Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra
LT3019153T (lt) 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
KR102462058B1 (ko) 2014-10-08 2022-11-01 잠본쏘시에떼퍼아찌오니 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물
WO2018059390A1 (fr) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 Composition pharmaceutique
WO2018206618A1 (fr) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. Procédé de préparation d'une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
US11931368B2 (en) 2017-09-29 2024-03-19 Crititech, Inc. Glucocorticoid “nintedanib” particles and their use
ES2953293T3 (es) * 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
WO2020088984A1 (fr) 2018-10-30 2020-05-07 Chiesi Farmaceutici S.P.A. Appareil pour administrer des médicaments à des patients ventilés mécaniquement
MX2022003427A (es) 2019-09-24 2022-04-18 Chiesi Farm Spa Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.
GB202012742D0 (en) 2020-08-14 2020-09-30 Norton Waterford Ltd An inhalable medicament
US20250050042A1 (en) * 2021-12-21 2025-02-13 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1944018A1 (fr) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation
EP1982709A1 (fr) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme
WO2010097188A1 (fr) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB0914240D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Steroid solvates
WO2011038872A1 (fr) * 2009-10-02 2011-04-07 Chiesi Farmaceutici S.P.A. Formulations d'aérosol pharmaceutique de formotérol et de dipropionate de béclométasone
WO2011120779A1 (fr) * 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Procédé de préparation de particules d'excipient pour poudres sèches à inhaler
RU2580312C2 (ru) 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
HUE069624T2 (hu) * 2012-01-25 2025-03-28 Chiesi Farm Spa Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra
LT3019153T (lt) * 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba

Also Published As

Publication number Publication date
AU2013211656B2 (en) 2017-07-13
HRP20221433T1 (hr) 2023-01-06
EP2806855A1 (fr) 2014-12-03
PT3527199T (pt) 2022-11-08
HUE060402T2 (hu) 2023-02-28
TWI559940B (en) 2016-12-01
PL3527199T3 (pl) 2022-12-12
EA026267B1 (ru) 2017-03-31
DK3527197T3 (da) 2022-10-24
PE20141703A1 (es) 2014-11-24
EP3020394A1 (fr) 2016-05-18
EA201690187A1 (ru) 2016-05-31
SI3527198T1 (sl) 2025-03-31
ES2929807T3 (es) 2022-12-01
PL2806855T3 (pl) 2018-12-31
EP3527199A1 (fr) 2019-08-21
RS63706B1 (sr) 2022-11-30
HRP20230147T1 (hr) 2023-03-31
LT3527199T (lt) 2022-12-12
CN105726548A (zh) 2016-07-06
JP2015508416A (ja) 2015-03-19
ES2929137T3 (es) 2022-11-25
RS63759B1 (sr) 2022-12-30
LT3527197T (lt) 2022-11-25
EP3527196B1 (fr) 2022-09-07
LT2806855T (lt) 2018-10-10
EA031566B1 (ru) 2019-01-31
CO7010836A2 (es) 2014-07-31
PH12014501565A1 (en) 2014-10-08
FI3527198T3 (fi) 2024-12-13
US20180296573A1 (en) 2018-10-18
CY1125579T1 (el) 2026-02-25
JP6104282B2 (ja) 2017-03-29
PH12014501565B1 (en) 2014-10-08
US20130189324A1 (en) 2013-07-25
HRP20221432T1 (hr) 2023-01-06
DK3527199T3 (da) 2022-10-24
EA201491281A1 (ru) 2014-12-30
EP3527197A1 (fr) 2019-08-21
KR20170116234A (ko) 2017-10-18
PL3412277T3 (pl) 2023-06-19
AU2013211656A1 (en) 2014-07-24
HUE060421T2 (hu) 2023-02-28
CA2862548A1 (fr) 2013-08-01
NZ627837A (en) 2016-04-29
HUE040525T2 (hu) 2019-03-28
PT3527198T (pt) 2024-12-04
SG11201404350PA (en) 2014-08-28
PT2806855T (pt) 2018-09-28
MX355729B (es) 2018-04-27
CN105726548B (zh) 2019-05-14
HRP20221431T1 (hr) 2023-01-06
MY165888A (en) 2018-05-18
BR112014017481A8 (pt) 2021-06-15
ES2938466T3 (es) 2023-04-11
ES2996893T3 (en) 2025-02-13
HRP20241638T1 (hr) 2025-02-14
CL2014001966A1 (es) 2014-11-14
DK3527198T3 (da) 2024-10-28
ZA201405464B (en) 2015-12-23
SI3412277T1 (sl) 2023-03-31
US10946029B2 (en) 2021-03-16
KR20150089093A (ko) 2015-08-04
CY1125595T1 (el) 2026-02-25
PT3412277T (pt) 2023-02-14
US8778402B2 (en) 2014-07-15
FI3412277T3 (fi) 2023-03-23
ES2928688T3 (es) 2022-11-22
ES2683254T3 (es) 2018-09-25
GEP201706767B (en) 2017-11-10
DK3527196T3 (da) 2022-10-24
HUE060705T2 (hu) 2023-04-28
HUE069624T2 (hu) 2025-03-28
RS63952B1 (sr) 2023-02-28
EP3527199B1 (fr) 2022-09-07
US10028964B2 (en) 2018-07-24
WO2013110632A1 (fr) 2013-08-01
KR101560288B1 (ko) 2015-10-14
MX2014008631A (es) 2014-08-21
KR101895279B1 (ko) 2018-09-05
KR20140114374A (ko) 2014-09-26
EP3412277A1 (fr) 2018-12-12
RS63761B1 (sr) 2022-12-30
BR112014017481A2 (pt) 2017-06-13
CN104080444A (zh) 2014-10-01
PL3527198T3 (pl) 2025-01-27
LT3527196T (lt) 2022-11-25
EP3412277B1 (fr) 2022-12-14
EP3527197B1 (fr) 2022-09-07
EP3527198B1 (fr) 2024-10-09
CA2862548C (fr) 2020-07-07
PL3527196T3 (pl) 2022-11-21
MX368199B (es) 2019-09-24
TN2014000322A1 (en) 2015-12-21
RS57637B1 (sr) 2018-11-30
UA115543C2 (uk) 2017-11-27
EP2806855B1 (fr) 2018-07-11
EP3527196A1 (fr) 2019-08-21
HUE061566T2 (hu) 2023-07-28
AR089805A1 (es) 2014-09-17
KR101786586B1 (ko) 2017-10-18
TW201334810A (zh) 2013-09-01
US20150164915A1 (en) 2015-06-18
CN104080444B (zh) 2017-06-20
HK1200021A1 (en) 2015-07-31
DK3412277T3 (da) 2023-02-20
PT3527196T (pt) 2022-10-18
DK2806855T3 (en) 2018-09-03
LT3412277T (lt) 2023-04-25
PT3527197T (pt) 2022-10-26
HRP20181550T1 (hr) 2018-11-30
PL3527197T3 (pl) 2022-11-21
IL233784A0 (en) 2014-09-30
CY1120684T1 (el) 2019-12-11
SI2806855T1 (sl) 2018-11-30
EP3527198A1 (fr) 2019-08-21

Similar Documents

Publication Publication Date Title
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IN2014DN10548A (fr)
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
ZA201603342B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
PH12015501596B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY166014A (en) Combination therapy methods for treating proliferative diseases
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
MX2016002408A (es) Metodos para el tratamiento de trastornos oticos pediatricos.
NZ701553A (en) Medicine comprising combination of general anesthetic drug and hydrogen
MX2015007280A (es) Terapia de combinacion para cancer.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
Breccia Dasatinib/vincristine
MA38782B1 (fr) Formulation de poudre sèche comportant un anticholinergique, un corticostéroïde et un bêta-adrénergique pour l'administration par inhalation
HK1238545A1 (en) Combination therapies
GR1008039B (el) Σταθερο ενεσιμο φαρμακευτικο σκευασμα ενος αγωνιστη των υποδοχεων της βιταμινης d και μεθοδος για την παρασκευη αυτου
MY187672A (en) Pharmaceutical preparation for anaesthetic use and associated preparation process